Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RIPK4 is associated with altered bioenergetics and invasive in melanoma three-dimensional models.

Scientific reports·2026
Same author

Cholesterol content and membrane properties in metastatic melanoma compared to primary melanoma: an EPR-based study.

International journal of radiation biology·2026
Same author

Prognostic Significance of Selected Tumor Stroma Parameters in Patients with HER2-Positive Breast Cancer Treated with Adjuvant Trastuzumab.

Cancers·2026
Same author

RIPK4 function interferes with melanoma cell adhesion and metastasis.

Molecular oncology·2026
Same author

Enhancing structural insights for advanced drug discovery by mitigating protein crystal damage.

Expert opinion on drug discovery·2025
Same author

Loss of Y chromosome in Alzheimer's patients co-occurs with somatic mutations beyond CHIP drivers.

Life science alliance·2025

Related Experiment Video

Updated: Aug 10, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Vemurafenib and Dabrafenib Downregulates RIPK4 Level.

Ewelina Madej1, Anna A Brożyna2, Agnieszka Adamczyk3

  • 1Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 7 Gronostajowa Street, 31-387 Krakow, Poland.

Cancers
|February 11, 2023
PubMed
Summary

BRAF inhibitors (BRAFi) like vemurafenib and dabrafenib may directly bind to receptor-interacting protein kinase 4 (RIPK4), an off-target. Inhibiting RIPK4 reduces melanoma cell proliferation and enhances BRAFi efficacy.

Keywords:
RIPK4dabrafenibdrug targetingmelanomatargeted therapiesvemurafenib

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

Related Experiment Videos

Last Updated: Aug 10, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Melanoma with BRAF V600E mutation is treated with BRAF kinase inhibitors (BRAFi).
  • Melanoma cells develop resistance to monotherapy BRAFi.
  • Receptor-interacting protein kinase 4 (RIPK4) is a potential oncogene in melanoma with structural similarity to BRAF.

Purpose of the Study:

  • To investigate the impact of BRAFi on RIPK4 in melanoma.
  • To explore RIPK4 as a potential off-target for BRAFi.
  • To understand RIPK4's role in melanoma progression and BRAFi resistance.

Main Methods:

  • In silico sequence and structural analysis of BRAF and RIPK4.
  • Treatment of BRAF-mutated and wild-type melanoma cells with vemurafenib and dabrafenib.
  • Analysis of ERK1/2 activity, RIPK4 protein levels, and FAK/AKT pathway.
  • RIPK4 gene silencing and assessment of cell proliferation, apoptosis, and necroptosis.

Main Results:

  • BRAFi showed high binding affinity to RIPK4, suggesting it as a potential off-target.
  • BRAFi inhibited ERK1/2 and reduced RIPK4 levels in BRAF-mutated melanoma cells.
  • RIPK4 downregulation inhibited cell proliferation and the FAK/AKT pathway, enhancing BRAFi efficiency.
  • RIPK4 silencing did not induce apoptosis or necroptosis.

Conclusions:

  • RIPK4 may be an off-target for BRAF inhibitors in melanoma treatment.
  • Targeting RIPK4 could be a strategy to overcome BRAFi resistance and inhibit melanoma progression.
  • Further research is needed to validate RIPK4 as a therapeutic target in melanoma.